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D22S275 2--1 NF2CA3 1 --2 D22S268 2 -n-3 D22S275 2--1 NF2CA3 1 --2 D22S268 2 --4 Abstract A two generation family with neurofibromatosis type 2 (NF2) is presented in which a family member requested presymptomatic molecular diagnosis. Since the consultand's mother had clinically well defined NF2, he was quoted to be at 50% risk of carrying an NF2 mutation. Mutation screening in the mother did not show the causative mutation and, consequently, presymptomatic testing was based on linkage analysis. This showed that the consultand carried the high risk chromosome 22. Subsequent mutation screening of his clinically affected sister showed a nonsense mutation, R262X in exon 8 evoked reflexes (BAER) were both normal. During follow up there was no change.
Her daughter (II.2) had very poor balance and diminished corneal reflexes bilaterally on physical and neurological examination. Audiology showed bilateral sensorineural hearing loss, more marked on the right. BAER results were in accordance with retrocochlear pathology. MRI showed bilateral vestibular schwannomas as well as multiple small cranial tumours (meningiomas and schwannomas) and several small spinal schwannomas.
Initial mutation analysis in the mother using a combined SSCP/heteroduplex analysis approach" did not detect a mutation in the NF2 gene. However, this was a two generation nt 784 family, so linkage analysis was potentially able to provide presymptomatic testing. Subsequent testing with microsatellite markers showed that the family was informative with NF2CA3, a polymorphic marker located within the NF2 gene," as well as with the flanking extragenic markers D22S275" and D22S268.'4 Therefore, it was decided to perform presymptomatic testing in IL.1 based on linkage analysis. The results for all three markers indicated that I1.1 had inherited the same maternal chromosome 22 as his sister, giving a risk of >99.9% that he would be affected (fig 1) . Consequently, he was counselled as high risk and was monitored accordingly. Some doubt still existed over the result, given the complete absence of tumours compared to his sister, and therefore mutation screening of the NF2 gene in I.1 was undertaken. This identified an SSCP shift in exon 8 of the NF2 gene which was subsequently sequenced as a nonsense mutation, R262X (nt 784C>T) (data not shown). In order to confirm the presence of R262X in II.2, and to facilitate screening of other members of the same family, a restriction generating (RG) primer was designed to engineer the creation of a novel DdeI site in the presence of 784C>T. The sequence of the R262X RG PCR primer (R262X-RGR) was 5'-CCTTGTCACTGT ACGAGATGTCTC-3' and this was used in conjunction with the exon 8 forward primer described by Merel et al,' (NF2-8F) 5'-CCACAGAATAAAAAGGGCAC-3'. The predicted fragment sizes were 70 and 69 bp for the normal allele and 70, 45, and 24 bp for 784C>T. In practice the 24 bp fragment could not be seen since it was obscured by the residual primers from the PCR reaction. II.2 showed the expected novel 45 bp fragment using the RG-PCR assay, whereas these were clearly not present in I.1 (fig 2) . Interestingly I.2 showed a faint 45 bp signal indicating that the stoichiometry of the normal versus mutant alleles was not the 1:1 ratio present in I.2.
Comparative dye primer cycle sequencing of exon 8 of I.2, II.1, and II.2 was then undertaken, to confirm the findings from the RG-PCR test and provide an estimate of the degree of mosaicism in 1.2 (fig 3) . IL.1 showed the same pattern at residue 784 as a normal control, confirming that he had not inherited R262X. II.2 was clearly heterozygous for 784C>T although the C and T peaks were not of equal height. I.2 clearly showed the presence of a T peak at 784 although its height was patently lower than that in I.2. To give a quantitative estimate of the degree of mosaicism in I.2, the heights of the C and T peaks at nt 784 were measured in the normal control and in II.2. They were then normalised against the height of the neighbouring C peak at nt 783. These measurements set the 100% to 50% values for 784C and 0% to 50% values for 784T. The peak heights of 784C and 784T in I.2 were then interpolated on a graph obtained by joining the points derived from the normal control and II.2. This gave an estimated contribution of 81.3% for 784C and 18.7% for 784T equat-ing to I.2 carrying the 784C>T mutation in 37.4% of her lymphocytes.
Clearly mosaicism was the cause of the misleading result in the presymptomatic test by linkage analysis in this family. A similar family study for retinoblastoma has recently been reported by Thonney et Mosaicism could be a common mechanism in other autosomal dominant diseases with a high mutation rate.' It could also be an explanation for apparent anticipation effects and variable expression between the first and second generation.9 17 18 In this family, both mother and daughter had their first signs in their early twenties. At the age of 47 the mother is doing surprisingly well, despite the burden of tumours. It is too early to comment on the course of the disease in her daughter.
In conclusion, caution has to be exercised when giving results of linkage tests which imply a very high risk to people in the second generation.
